DGX Stock Summary and Trading Ideas (Quest Diagnostics | NYSE:DGX)

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Quest Diagnostics trades on the NYSE stock market under the symbol DGX.

As of June 8, 2026, DGX stock price declined to $197.21 with 682,734 million shares trading.

DGX has a beta of -0.26, meaning it tends to be less sensitive to market movements. DGX has a correlation of 0.02 to the broad based SPY ETF.

DGX has a market cap of $21.83 billion. This is considered a Large Cap stock.

Last quarter Quest Diagnostics reported $3 billion in Revenue and $2.50 earnings per share. This beat revenue expectation by $74 million and exceeded earnings estimates by $.14.

In the last 3 years, DGX traded as high as $213.50 and as low as $119.59.

The top ETF exchange traded funds that DGX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.

DGX has underperformed the market in the last year with a return of +15.0%, while the SPY ETF gained +24.6%. In the last 3 month period, DGX fell short of the market, returning -0.6%, while SPY returned +10.2%. However, in the most recent 2 weeks DGX has outperformed the stock market by returning +1.0%, while SPY returned -0.9%.

DGX support price is $197.60 and resistance is $202.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DGX shares will trade within this expected range on the day.